Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-CD47 agent-based treatment of CD20-positive cancer

Anti-CD47 agent-based treatment of CD20-positive cancer

US Patent 11891450 · Granted Feb 6, 2024

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies2025
Methods for achieving therapeutically effective doses of anti-CD47 agents2025
Methods for treating myeloma by achieving therapeutically effective doses of ant2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies2025
Dosing parameters for CD47 targeting therapies to hematologic malignancies2025
Methods for manipulating phagocytosis mediated by CD472024
Treatment of cancer with dual targeting of CD47 and EGFR2024
Anti-CD47 agent-based ovarian cancer therapy2023
Anti-CD47 agent-based ovarian cancer therapy2023
Anti-CD47 agent-based ovarian cancer therapy2023